Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 10/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.40 |
| ▸ | KCNJ6 | P48051 | 6/20 | 0.38 |
| ▸ | KCNJ5 | P48544 | 6/20 | 0.38 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20570414 | 0.76 | DRD2 (0.37) | KCNJ6KCNJ5KCNJ3DRD2DRD4 | |
| SCHEMBL20568381 | 0.74 | PDE5A (0.41) | KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL27983382 | 0.70 | CNR1 (0.52) | DRD3SLC22A12CNR2 | |
| SCHEMBL1231553 | 0.70 | CNR2 (0.46) | CNR2 | |
| SCHEMBL20568480 | 0.69 | ALDH1A1 (0.42) | ADORA1ADORA3KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL27166942 | 0.69 | PDK1 (0.42) | KCNJ6KCNJ5KCNJ3DRD2DRD4 | |
| SCHEMBL20569484 | 0.69 | KCNJ6 (0.49) | ADORA1ADORA3KCNJ6KCNJ5KCNJ3 | |
| SCHEMBL18096451 | 0.68 | PTGER4 (0.47) | CNR2 | |
| SCHEMBL25680697 | 0.67 | CYP19A1 (0.44) | ADORA1ADORA3ADORA2ADRD2DRD4 | |
| SCHEMBL22125717 | 0.66 | POLB (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2021-05-13 | — | — | US | disclosed |
| EP-3630777-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | Oxford University Innovation Limited (GB) | 2020-04-08 | — | — | EP | disclosed |
| WO-2018215800-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2018-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210137886-A1 | INHIBITORS OF METALLO-BETA-LACTAMASES | MGAM, GAA, LCT | ADORA1 4200/4885ADORA3 4449/4885KCNJ6 2580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.